company background image
VRNA

Verona Pharma NasdaqGM:VRNA Stock Report

Last Price

US$10.60

Market Cap

US$928.7m

7D

11.0%

1Y

130.4%

Updated

05 Oct, 2022

Data

Company Financials +
VRNA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VRNA Stock Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.

Verona Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Verona Pharma
Historical stock prices
Current Share PriceUS$10.60
52 Week HighUS$14.69
52 Week LowUS$3.41
Beta0.46
1 Month Change2.91%
3 Month Change148.24%
1 Year Change130.44%
3 Year Change162.38%
5 Year Change-30.08%
Change since IPO-21.48%

Recent News & Updates

Sep 13

Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point

Summary Verona achieved primary and secondary endpoints in phase 3 ENHANCE-2 study using ensifentrine as maintenance treatment of COPD. Results from the second phase 3 study, ENHANCE-1, also using ensifentrine as maintenance treatment of COPD is expected by end of 2022. The global market opportunity for Chronic Obstructive Pulmonary Disease is expected to reach $14.1 billion by 2025. With ensifentrine activating the Cystic Fibrosis Transmembrane Conductance Regulator, it might be worth exploring as a possible treatment for patients with Cystic Fibrosis. Verona Pharma (NASDAQ:VRNA) is a great speculative biotech play to look into. That's because it already reported positive results from one study using ensifentrine for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). It has a data readout from its second phase 3 study towards the end of 2022, which if also successful, I believe could be a huge value inflection point for this biotech. This drug is unique because it has a dual targeting mechanism of action, allowing it to be different from other currently available therapies. Not only that, but it was noted that patients who received nebulized ensifentrine in the phase 3 ENHANCE-2 study, achieved both the primary and secondary endpoints. On top of that, it was able to reduce exacerbations in patients with COPD by 42% compared to placebo. This was one of the two phase 3 studies evaluating ensifentrine as a nebulized drug. The second phase 3 ENHANCE-1 study is expected to report results by the end of 2022. This would be a major catalyst for investors to look forward to. It is still risky, because there is no guarantee that this second phase 3 study will be successful. Still, the drug did well in one phase 3 study and in a prior phase 2 study, meeting statistical significance in both instances. Patients in these studies were on background therapies which also likely helped. If the second phase 3 study is successful (ENHANCE-1), then the company will be able to file a New Drug Application (NDA) to the FDA for ensifentrine in the 1st half of 2023. There is an opportunity to expand upon the potential territory for which this drug can be marketed as maintenance treatment for COPD. This is because Verona Pharma's partner Nuance received clearance to initiate a phase 1 and phase 3 study, using ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD), in mainland China. Lastly, with the way the drug was developed, it also has the ability to activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). As such, ensifentrine could also be advanced for the treatment of patients with Cystic Fibrosis. With proof of concept established for ensifentrine as a maintenance treatment for COPD, plus the ability to expand its potential towards another market share and indication, these are the reasons why I believe it is a great speculative biotech play to look into. Ensifentrine For The Treatment Of Patients With Chronic Obstructive Pulmonary Disease The main drug in the pipeline is ensifentrine, which is being developed for the treatment of patients with chronic obstructive pulmonary disorder (COPD). But before diving into COPD itself and the positive clinical results from one of the two phase 3 studies, it's important to note the mechanism of action of this drug. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. PDE3 and PDE4 have anti-inflammatory and bronchodilator effects, which both when combined have synergistic properties. This, instead of just using a PDE3 inhibitor or a PDE4 inhibitor alone. There was a challenge though in that prior drugs such as this were developed for oral use (pill form). The problem is that the efficacy was not as great when delivered in such a fashion, plus the side effects. As such, Verona Pharma developed the nebulized version which was explored in the positive phase 3 study. With this type of delivery, the drug could not only work better because it reaches the point of interest quicker but also reduce systemic side effects as well. "Nebulized" means converting a liquid substance like ensifentrine to spray form. Chronic obstructive pulmonary disease is where the airflow of a person is blocked, which in turn makes it hard for them to breathe. You may have heard of chronic bronchitis or gotten it, this is one condition as part of COPD. Another, would be something known as emphysema, which is where the air sacs in the lungs become damaged. It is estimated that there are 3 million cases in the United States alone each year. The global market opportunity for Chronic obstructive pulmonary disease is expected to reach $14.1 billion by 2025. Symptoms that these patients experience are as follows: Chronic coughing Wheezing constantly Shortness of breath I also view this space as an important one. That's because those with COPD have damage caused to the lungs that can't be reversed. Other oral steroids or rescue inhalers can control symptoms and minimize further damage to an extent. However, it's important that new treatments like ensifentrine help to further reduce damage in a more sustained fashion as a long-term treatment option. Once the damage is done to the lungs then there aren't many drugs which can reverse this effect. Moving on to the ENHANCE program itself, this was designed to set up two identical studies, which are set to recruit up to 800 COPD patients in each. Both of these studies are known as ENHANCE-1 and ENHANCE-2. The way that each of these studies were set up is that they treated these patients with nebulized ensifentrine as a monotherapy and then added a bronchodilator (another drug used to expand airway of the lungs) such as LAMA or LABA, and then compare it to placebo. About 20% of patients received another type of therapy to help expand lung airways such as ICS (inhaled corticosteroids). Both of these studies were designed to treat patients over a 24-week period. However, a key difference is that ENHANCE-1 is also evaluating patients for long term safety as well over a 48 week period. Thus, why this phase 3 study is taking a bit longer to complete. As I noted in the beginning of this article, the ENHANCE-2 trial met the primary endpoint and all secondary endpoints as well. What I want to key in on, which is the most important for this drug to ever receive approval would be the primary endpoint. The primary endpoint is improvement in lung function as measured by average Forced Expiration Volume 1 (FEV1) AUC (Area under the curve) 0-12 hours post dose at week 12. It was shown that ensifentrine was able to achieve a change from baseline in average FEV1 AUC 0-12 hours post dose at week 14 of 94 mL. This was statistically significant compared to placebo with a p-value of p<0.0001. Another solid finding was that patients who received ensifentrine achieved a 42% reduction in the rate of moderate to severe COPD exacerbations over a 24-week period. "Exacerbations" means worsening of COPD symptoms or in other words getting much worse in disease. With ENHANCE-2 meeting the primary endpoint, the wait and see moment now is if the other late-stage study ENHANCE-1 can also meet the very same primary endpoint for COPD patients. Results from this other phase 3 study are going to be released by the end of 2022. This is all great so far, but there is one stipulation which must first be achieved before the company can move on towards potential filing of a regulatory application. It goes to the upcoming data readout by the end of 2022 from ENHANCE-1. This second phase 3 study must also meet the very same primary endpoint. If it does, then Verona will be able to file a New Drug Application to the FDA for the potential approval of ensifentrine for COPD by the 1st half of 2023. However, if this other study doesn't achieve the primary endpoint, then advancement will be up in the air. What do I mean by that? Well, the FDA may require an additional successful study or by a small percentage chance the drug may still be approved. There are opportunities for expansion though. One such opportunity is being able to get ensifentrine to market in China. That's because Verona Pharma made a licensing deal whereby Nuance Pharma could develop and commercialize ensifentrine as a maintenance treatment for COPD in Greater China. These territories include mainland China, Taiwan, Hong Kong and Macau. This was a $219 million strategic collaboration that was done back in June of 2021. Verona received an upfront payment of $40 million and has the potential to earn $179 million in possible clinical, regulatory and commercial milestone payment. Not only that, but it could earn up to double-digit royalties on net sales for products sold in China as well. About a month ago, Nuance Pharma got clearance to initiate both phase 1 and phase 3 studies with ensifentrine for COPD in China. Successful outcomes from both of these studies in that region would mean the possibly to expand the market opportunity for this treatment. Another expansion opportunity would be the potential for ensifentrine to be used for the treatment of patients with Cystic Fibrosis (CF). As I stated above, this drug has a profound effect on being able to activate CFTR, which is important for reducing mucous viscosity in patients with CF. Having said that, this is another avenue for which Verona Pharma can explore to expand the potential opportunity it has with ensifentrine. Financials According to the 10-Q SEC Filing, Verona Pharma had $111 million cash as of June 30, 2022. Throughout the years it has been enacting several measures to raise cash. In March of 2021, it entered into an open market sale agreement with Jefferies LLC to sell shares of our ordinary shares, in the form of ADSs, with aggregate sales noted up to $100 million. Such shares under this agreement could be sold from time to time through the "at the market" equity offering program. During the 6 months ending June 30, 2022 it sold about 80,696 shares under this ATM Program (translates to 10,087 ADSs). It raised approximately $0.1 million after deducting expenses. If it has a need to do so, it still can sell $99.2 million worth of ordinary shares (As ADSs) under this ATM Program. In November 2020, it entered into a loan facility agreement with Silicon Valley Bank of up to $30 million. At the time of closing it got a term loan advance of $5 million. There is an aggregate amount of $10 million available to certain conditions and milestones and then a term loan advance of $15 million subject to clinical developments and other specified conditions. It believed that it would have enough cash to fund its operations until the end of 2023. However, it chose not to do so. As such, the very same day it announced its earnings update, it also disclosed an upsized public offering. It sold a total of 12,400,000 American Depositary Shares ("ADSs") each consisting of 8 ordinary shares of Verona Pharma. In total, it raised an aggregate amount of gross proceeds of $130.2 million before deducting expenses. With this cash raise done just recently, it has now extended its cash runway to mid-2024. Although, my guess is that it may choose to raise cash again at the end of 2023 before it runs out in mid-2024. Risks To Business There are several risks investors should be aware of before investing into this name. The first risk deals with the ENHANCE program. Even though the ENHANCE-2 study met the primary endpoint, using nebulized ensifentrine for the maintenance treatment of patients with COPD, that doesn't mean that the ENHANCE-1 study will also meet on the primary endpoint. Even if this second phase 3 study is successful, the NDA filing must still be accepted by the FDA itself in the 1st half of 2023. Plus, the FDA will have to then review and approve ensifentrine for marketing in the United States.

Aug 19

Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials

Verona Pharma's (NASDAQ:VRNA) (OTC:VNAPF) development partner Nuance Pharma's application seeking to start phase 1 and phase 3 studies of ensifentrine for lung disease in Mainland China received clearance from the Center of Drug Evaluation (CDE). Nuance had filed investigational new drug (IND) to conduct both studies of ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). "This is an important milestone and, based on our recent positive Phase 3 results from our ENHANCE-2 trial in COPD, we remain confident about the potential of ensifentrine to address the urgent global need for a novel treatment for COPD," said Verona President and CEO David Zaccardelli. In 2021 Verona granted Nuance exclusive rights to develop and commercialize ensifentrine in Greater China in a deal worth up to $219M. Verona had received $25M cash upfront  and an equity interest worth $15M in Nuance Biotech, the parent company of Nuance Pharma. Verona is also eligible for royalties. VRNA +4.45% to $13.39 premarket Aug. 19

Shareholder Returns

VRNAUS PharmaceuticalsUS Market
7D11.0%0.02%1.9%
1Y130.4%6.2%-18.8%

Return vs Industry: VRNA exceeded the US Pharmaceuticals industry which returned 5.8% over the past year.

Return vs Market: VRNA exceeded the US Market which returned -18.2% over the past year.

Price Volatility

Is VRNA's price volatile compared to industry and market?
VRNA volatility
VRNA Average Weekly Movement17.0%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement7.0%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: VRNA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: VRNA's weekly volatility has increased from 12% to 17% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200525Dave Zaccardellihttps://www.veronapharma.com

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler.

Verona Pharma Fundamentals Summary

How do Verona Pharma's earnings and revenue compare to its market cap?
VRNA fundamental statistics
Market CapUS$928.71m
Earnings (TTM)-US$54.81m
Revenue (TTM)US$40.00m

23.2x

P/S Ratio

-16.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VRNA income statement (TTM)
RevenueUS$40.00m
Cost of RevenueUS$0
Gross ProfitUS$40.00m
Other ExpensesUS$94.81m
Earnings-US$54.81m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.63
Gross Margin100.00%
Net Profit Margin-137.04%
Debt/Equity Ratio4.5%

How did VRNA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is VRNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VRNA?

Other financial metrics that can be useful for relative valuation.

VRNA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue20.6x
Enterprise Value/EBITDA-16.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does VRNA's PS Ratio compare to its peers?

VRNA PS Ratio vs Peers
The above table shows the PS ratio for VRNA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average23.5x
MRNS Marinus Pharmaceuticals
9.4x48.5%US$260.8m
RVNC Revance Therapeutics
23.8x44.0%US$2.4b
FULC Fulcrum Therapeutics
28.6x45.3%US$413.2m
ITCI Intra-Cellular Therapies
32.4x45.2%US$4.5b
VRNA Verona Pharma
23.2x66.6%US$928.7m

Price-To-Sales vs Peers: VRNA is good value based on its Price-To-Sales Ratio (23.2x) compared to the peer average (23.5x).


Price to Earnings Ratio vs Industry

How does VRNA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: VRNA is expensive based on its Price-To-Sales Ratio (23.2x) compared to the US Pharmaceuticals industry average (3x)


Price to Sales Ratio vs Fair Ratio

What is VRNA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VRNA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23.2x
Fair PS Ratio45.6x

Price-To-Sales vs Fair Ratio: VRNA is good value based on its Price-To-Sales Ratio (23.2x) compared to the estimated Fair Price-To-Sales Ratio (45.6x).


Share Price vs Fair Value

What is the Fair Price of VRNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VRNA ($10.6) is trading below our estimate of fair value ($258.09)

Significantly Below Fair Value: VRNA is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Verona Pharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


46.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VRNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VRNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VRNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VRNA's revenue (66.6% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: VRNA's revenue (66.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VRNA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Verona Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-22.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VRNA is currently unprofitable.

Growing Profit Margin: VRNA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VRNA is unprofitable, and losses have increased over the past 5 years at a rate of 22.9% per year.

Accelerating Growth: Unable to compare VRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VRNA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: VRNA has a negative Return on Equity (-49.44%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Verona Pharma's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: VRNA's short term assets ($138.6M) exceed its short term liabilities ($38.9M).

Long Term Liabilities: VRNA's short term assets ($138.6M) exceed its long term liabilities ($5.1M).


Debt to Equity History and Analysis

Debt Level: VRNA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if VRNA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VRNA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: VRNA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 18.9% each year


Discover healthy companies

Dividend

What is Verona Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Verona Pharma Dividend Yield vs Market
How does Verona Pharma dividend yield compare to the market?
SegmentDividend Yield
Company (Verona Pharma)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.5%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (Verona Pharma)n/a

Notable Dividend: Unable to evaluate VRNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VRNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VRNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VRNA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VRNA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Dave Zaccardelli (57 yo)

2.67yrs

Tenure

US$1,123,304

Compensation

Dr. David S. Zaccardelli, also known as Dave, Pharm D., has been President, Chief Executive Officer and Executive Director of Verona Pharma plc since February 1, 2020. Dr. Zaccardelli has been Director of...


CEO Compensation Analysis

Dave Zaccardelli's Compensation vs Verona Pharma Earnings
How has Dave Zaccardelli's remuneration changed compared to Verona Pharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$55m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$1mUS$273k

-US$56m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$87m

Mar 31 2021n/an/a

-US$74m

Dec 31 2020US$18mUS$229k

-US$65m

Compensation vs Market: Dave's total compensation ($USD1.12M) is below average for companies of similar size in the US market ($USD3.98M).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: VRNA's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: VRNA's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGM:VRNA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Aug 22BuyUS$98,460Ai Biotechnology LlcCompany600,000US$0.16

Ownership Breakdown

What is the ownership structure of VRNA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,428,2782.8%
Private Companies6,988,9568.0%
VC/PE Firms17,310,36219.8%
Institutions20,781,85323.7%
General Public40,104,72245.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.9%.


Top Shareholders

Top 25 shareholders own 53.69% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.98%
Ai Biotechnology Llc
6,988,956$74.1m25.8%no data
6.88%
RA Capital Management, L.P.
6,030,768$63.9m0%1.24%
6.5%
OrbiMed Advisors LLC
5,694,841$60.4m13.26%0.97%
6.37%
New Enterprise Associates, Inc.
5,584,753$59.2m9.32%2.38%
4.37%
Wellington Management Group LLP
3,828,149$40.6m1.31%0.01%
3.33%
Perceptive Advisors LLC
2,915,146$30.9m-4.24%0.88%
3.14%
Vivo Capital, LLC
2,749,918$29.1m0%2.5%
2.8%
Abingworth LLP
2,457,500$26.0m0%8.14%
1.59%
Novo Holdings A/S
1,390,453$14.7m0%0.02%
1.52%
Aisling Capital Management LP
1,332,485$14.1m0%8.77%
1.27%
Samsara BioCapital LLC
1,111,112$11.8m0%2.36%
1.27%
Foresite Capital Management, LLC
1,111,112$11.8m0%1.91%
1.16%
David Zaccardelli
1,020,105$10.8m1.89%no data
1.06%
Fairmount Funds Management LLC
926,602$9.8m0%1.67%
1.04%
Mark Hahn
913,890$9.7m1.69%no data
0.86%
Tekla Capital Management LLC
751,905$8.0m0%0.29%
0.57%
Woodline Partners LP
501,458$5.3m0%0.08%
0.51%
Medical Strategy GmbH, Asset Management Arm
444,440$4.7m3.23%0.3%
0.34%
Ikarian Capital, LLC
300,000$3.2m0%1.03%
0.3%
Schroder Investment Management North America Inc.
263,418$2.8m0%0.01%
0.28%
UOB Asset Management Ltd
242,134$2.6m0%0.16%
0.18%
venBio LLC
161,897$1.7m0%0.36%
0.13%
Claire Poll
110,861$1.2m11.31%no data
0.12%
Kathleen Rickard
105,308$1.1m-65.77%no data
0.12%
Jan-Anders Karlsson
105,277$1.1m0%no data

Company Information

Verona Pharma plc's employee growth, exchange listings and data sources


Key Information

  • Name: Verona Pharma plc
  • Ticker: VRNA
  • Exchange: NasdaqGM
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$928.710m
  • Shares outstanding: 87.61m
  • Website: https://www.veronapharma.com

Number of Employees


Location

  • Verona Pharma plc
  • 3 More London Riverside
  • London
  • Greater London
  • SE1 2RE
  • United Kingdom


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VRNANasdaqGM (Nasdaq Global Market)YesSPON ADR EACH REP 8 ORD SHSUSUSDApr 2017
I9SADB (Deutsche Boerse AG)YesSPON ADR EACH REP 8 ORD SHSDEEURApr 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/05 00:00
End of Day Share Price2022/10/05 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.